Association Between Angiotensin Receptor-Neprilysin Inhibition, Cardiovascular Biomarkers, and Cardiac Remodeling in Heart Failure With Reduced Ejection Fraction

被引:36
|
作者
Murphy, Sean P. [1 ]
Prescott, Margaret F. [2 ]
Maisel, Alan S. [3 ]
Butler, Javed [4 ]
Pina, Ileana L. [5 ]
Felker, G. Michael [6 ,7 ]
Ward, Jonathan H. [2 ]
Williamson, Kristin M. [2 ]
Camacho, Alexander [1 ]
Kandanelly, Ritvik R. [1 ]
Solomon, Scott D. [8 ,9 ]
Januzzi, James L. [1 ,9 ,10 ]
机构
[1] Massachusetts Gen Hosp, Yawkey 5984,55 Fruit St, Boston, MA 02114 USA
[2] Novartis Pharmaceut, E Hanover, NJ USA
[3] Univ Calif San Diego, Sch Med, La Jolla, CA 92093 USA
[4] Univ Mississippi, Med Ctr, Jackson, MS 39216 USA
[5] Detroit Med Ctr, Detroit, MI USA
[6] Duke Univ, Med Ctr, Durham, NC USA
[7] Duke Clin Res Inst, Durham, NC USA
[8] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA
[9] Harvard Med Sch, Boston, MA 02115 USA
[10] Baim Inst Clin Res, Boston, MA USA
关键词
biomarkers; echocardiography; heart failure; prospective studies; valsartan; SOLUBLE ST2; NATRIURETIC PEPTIDE; TROPONIN-T; PROGNOSTIC VALUE; ENALAPRIL; THERAPY;
D O I
10.1161/CIRCHEARTFAILURE.120.008410
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND: Sacubitril/valsartan (S/V) treatment is associated with reverse cardiac remodeling and reductions in biomarkers reflecting ventricular wall stress and myocardial injury, such as NT-proBNP (N-terminal pro-B-type natriuretic peptide), hscTnT (high-sensitivity cardiac troponin T), and soluble suppressor of tumorigenicity 2 (sST2). How longitudinal changes in these biomarkers analyzed collectively are associated with cardiac remodeling in patients with heart failure with reduced ejection fraction treated with S/V is uncertain. METHODS: In a prospective study of S/V in patients with heart failure with reduced ejection fraction, this prespecified exploratory analysis included patients with serially collected biomarkers and echocardiographic measures of cardiac remodeling through 12 months of treatment. A multivariate latent growth curve model assessed associations between simultaneous changes in biomarkers and left ventricular ejection fraction and left atrial volume index. RESULTS: Seven hundred fifteen out of 794 total study participants were included (mean age 65 years, 73% male). Mean baseline left ventricular ejection fraction and left atrial volume index were 29% and 40 mL/m(2), respectively. Adjusted geometric mean baseline concentrations for biomarkers included NT-proBNP of 649 pg/mL, hs-cTnT of 15.9 ng/ L, and sST2 of 24.7 ng/mL. Following initiation of S/V, circulating concentrations of NT-proBNP, hs-cTnT, and sST2 significantly decreased within 30 days and remained significantly different than baseline at all subsequent timepoints. From baseline to month 12, decreases in adjusted biomarker concentrations averaged -27.9% (95% CI, -35.1% to -20.7%; P<0.001) for NT-proBNP; -6.7% (95% CI, -8.8% to -4.7%; P<0.001) for hs-cTnT; and -1.6% (95% CI, -2.9% to -0.4%; P<0.001) for sST2. NT-proBNP concentrations were predictive of later changes in hs-cTnT. The magnitude of reductions in NT-proBNP and hs-cTnT concentrations associated with improvements in left ventricular ejection fraction and left atrial volume index. There was no association between changes in sST2 and changes in other measures. CONCLUSIONS: Following initiation of S/V, NT-proBNP, hs-cTnT, and sST2 concentrations decreased significantly. Longitudinal changes in NT-proBNP and hs-cTnT together associated with left atrial and left ventricular reverse remodeling.
引用
收藏
页数:10
相关论文
共 50 条
  • [21] Angiotensin receptor-neprilysin inhibitors and cardiac remodeling
    Ryazanov, A. S.
    Shikh, E. V.
    Makarovskaya, M. V.
    Kudryavtsev, A. A.
    BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH, 2023, 56
  • [22] Effects of angiotensin receptor neprilysin inhibition on pulmonary arterial stiffness in heart failure with reduced ejection fraction
    Mustafa Yenerçağ
    Uğur Arslan
    Seçkin Dereli
    Metin Çoksevim
    Mustafa Doğduş
    Ahmet Kaya
    The International Journal of Cardiovascular Imaging, 2021, 37 : 165 - 173
  • [23] Effects of angiotensin receptor neprilysin inhibition on pulmonary arterial stiffness in heart failure with reduced ejection fraction
    Yenercag, Mustafa
    Arslan, Ugur
    Dereli, Seckin
    Coksevim, Metin
    Dogdus, Mustafa
    Kaya, Ahmet
    INTERNATIONAL JOURNAL OF CARDIOVASCULAR IMAGING, 2021, 37 (01): : 165 - 173
  • [24] Timing of angiotensin receptor-neprilysin inhibitor initiation in patients with heart failure and reduced ejection fraction: data from the Swedish heart failure registry
    Stolfo, D.
    Lund, L.
    Benson, L.
    Kack, O.
    Lindberg, F.
    Sinagra, G.
    Dahlstrom, U.
    Savarese, G.
    EUROPEAN HEART JOURNAL, 2023, 44
  • [25] Comparison of Efficacy and Safety of Angiotensin Receptor-Neprilysin Inhibitors in Patients With Heart Failure With Reduced Ejection Fraction: A Meta-Analysis
    Haseeb, Muhammad Talha
    Aslam, Muhammad Nouman
    Avanteeka, Fnu
    Khalid, Umar Abdul Rehman
    Ahmad, Dewan Zubaer
    Senaratne, Mithum
    Almaalouli, Bsher
    Hirani, Shamsha
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (03)
  • [26] Clinical and Socioeconomic Determinants of Angiotensin Receptor-Neprilysin Inhibitor Prescription at Hospital Discharge in Patients With Heart Failure With Reduced Ejection Fraction
    Tran, Jeffrey S.
    Loveland, Macklin G.
    Alamer, Ahmad
    Pina, Ileana L.
    Sweitzer, Nancy K.
    CIRCULATION-HEART FAILURE, 2022, 15 (11) : E009395
  • [27] Outcomes of Angiotensin Receptor-Neprilysin Inhibitor Prescriptions for Patients with Heart Failure and Reduced Ejection Fraction in Real World Clinical Practice
    Malloy, Rhynn J.
    Smith, Katelyn V.
    Stern, Gretchen M.
    Desai, Akshay S.
    JOURNAL OF CARDIAC FAILURE, 2018, 24 (08) : S28 - S28
  • [28] Angiotensin Receptor-Neprilysin Inhibitor Therapy for Heart Failure With Preserved Ejection Fraction Improves Renal Outcomes
    Tobe, Sheldon W.
    Poon, Stephanie
    CIRCULATION, 2020, 142 (13) : 1246 - 1248
  • [29] FRAILTY AND UPTAKE OF ANGIOTENSIN RECEPTOR NEPRILYSIN INHIBITOR FOR HEART FAILURE WITH REDUCED EJECTION FRACTION
    Ko, Darae
    Lee, Yu-Chien
    Lin, Kueiyu Joshua
    Cheng, Susan
    Patorno, Elisabetta
    Glynn, Robert J.
    Tsacogianis, Theodore
    Kim, Dae Hyun
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2023, 81 (08) : 521 - 521
  • [30] Six months clinical and echocardiographic outcome of angiotensin receptor-neprilysin inhibitor therapy in heart failure patients with reduced ejection fraction
    Alnims, M. Mohammed
    Magdy, Abdelhamid
    Meguid, M. Abdel
    Ahmed, Shehata
    EUROPEAN JOURNAL OF HEART FAILURE, 2020, 22 : 82 - 83